MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • 2016 International Congress

    Efficacy and feasibility study of the Medido eletronic medication dispenser in Parkinson’s disease: A multicentre randomized controlled trial

    K. Hannink, L. ter Brake, A. Wertenbroek, K. Movig, J. van der Palen, L. Dorresteijn (Enschede, Netherlands)

    Objective: The aim of this randomized controlled study was to assess the effect of the electronic medication dispenser, Medido, on physical limitations in PD. Background:…
  • 2016 International Congress

    The effect of a structured medication review on quality of life in patients with Parkinson’s disease. An interim analysis

    A. Verbeek, N. Oonk, E. Munster, K. Movig, K. ter Huurne, H. Nijmeijer, J. van der Palen, L. Dorresteijn (Eerbeek, Netherlands)

    Objective: To investigate whether a structured medication review executed by a community pharmacist improves medication adherence and influences quality of life in patients with Parkinson's…
  • 2016 International Congress

    Effect of pharmacist-led interventions on motor symptoms and quality of life in Parkinson’s patients: A pilot study

    C. Stuijt, T.V. Laar (Groningen, Netherlands)

    Objective: Improvement of on-off symptoms in ambulatory patients with Parkinson's disease (PD) by introduction of a multi-faceted medication optimization program. This consisted of a patient…
  • 2016 International Congress

    Roles of combined functional catechol-o-methyltransferase genotypes in Chinese Parkinson’s disease: A cross-sectional survey

    Y. Qian, X. Yang, S. Xu, J. Liu, Q. Xiao (Shanghai, People's Republic of China)

    Objective: To investigate the association of the most common functional catechol-O-methyltransferase (COMT) gene haplotypes with risk to develop of Parkinson's disease (PD) and the association…
  • 2016 International Congress

    Safety and efficacy of pardoprunox for patients with Parkinson’s disease: A meta-analysis

    N. Elsagheer, H. Ahmed, A. Attia, K. Awad, E. Ezzat, M. Abd Elaleem Aziz, A. Negida (Beni Suef, Egypt)

    Objective: The aim of this meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the safety and efficacy of Pardoprunox for Patients…
  • 2016 International Congress

    The kinase Fyn mediates levodopa induced dyskinesias in Parkinson´s disease

    J.E. Ferrario, S. Sanz-Blasco, M. Bordone, A. Damianich, A. Bernardi, G. Gomez, I. Taravini, E. Avale, O. Gershanik (Buenos Aires, Argentina)

    Objective: To pharmacologically manipulate the kinase Fyn as a novel target to control levodopa induced dyskinesias. Background: The management of levodopa induced dyskinesias (LID) in…
  • 2016 International Congress

    Motor fluctuations in relation to plasma concentrations following a single-dose of levodopa/carbidopa microtablets in advanced Parkinson’s disease

    M. Senek, H. Askmark, S.M. Aquilonius, F. Bergquist, R. Constantinescu, A. Ericsson, S. Lycke, A. Medvedev, M. Memedi, F. Ohlsson, J. Spira, J. Westin, D. Nyholm (Uppsala, Sweden)

    Objective: The aim of this study was to characterize the levodopa and carbidopa plasma concentration in relation to blinded motor function ratings. This is a…
  • 2016 International Congress

    Changes in serum amino acid levels with progression of Parkinson’s disease

    M. Figura, K. Kusmierska, E. Bucior, S. Szlufik, D. Koziorowski, Z. Jamrozik, A. Friedman, P. Janik (Warsaw, Poland)

    Objective: The purpose of this study was to analyze changes in serum amino acid profile with progression of Parkinson's disease (PD). Background: PD is a…
  • 2016 International Congress

    Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson’s disease center

    S. Patel, X. Garcia, M.E. Mohammad, X.X. Yu, K. Vlastaris, K. O'Donnell, K. Sutton, H.H. Fernandez (Cleveland, OH, USA)

    Objective: To describe the frequency, characteristics and potential risk factors for Dopamine Agonist Withdrawal Syndrome (DAWS). Background: Dopamine agonists are a mainstay of treatment for…
  • 2016 International Congress

    Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns

    J. Morgan, M. Stacy, R. Rubens, S. Khanna, S. Gupta (Augusta, GA, USA)

    Objective: Describe the dosing patterns in advanced Parkinson's disease (PD) patients who completed conversion to IPX066 from other levodopa formulations. Background: IPX066 is an extended-release…
  • « Previous Page
  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley